Tirzepatide cost in 2026
Zepbound (obesity) / Mounjaro (type 2 diabetes). Chronic weight management, type 2 diabetes, obstructive sleep apnea.
Tirzepatide (Zepbound, Mounjaro) lists around $1,059–$1,300 per month at retail depending on dose. Real out-of-pocket cost varies dramatically with insurance coverage, savings programs, and pharmacy choice. Below is the realistic range by scenario as of April 2026.
Realistic cost by scenario
| Scenario | Estimated / month |
|---|---|
| Insurance covers Zepbound for obesityDepends on plan formulary tier | $25–$75 copay |
| Insurance covers Mounjaro for T2D | $25–$75 copay |
| LillyDirect Self Pay (Zepbound vial, no insurance)Eligibility varies by dose and supply | $349–$499 |
| Uninsured cash pay at retail pharmacy (pen)Full list | $1,059–$1,300 |
| Savings card + commercial insurance that doesn't cover obesityWith Zepbound Savings Card | ~$550 |
Manufacturer savings programs
Eligibility: Uninsured patients, or commercially insured patients whose plan doesn't cover Zepbound
Best case: $349/mo (2.5 mg) to $499/mo (5 mg) for the vial form
Eligibility: Commercially insured, not Medicare/Medicaid
Best case: As low as $25 if plan covers; ~$550 if plan doesn't cover
Eligibility: Commercially insured T2D patient, not Medicare/Medicaid
Best case: As low as $25 if covered
Frequently asked
Is Zepbound covered by insurance?
Coverage for obesity medications varies widely. Some employer plans cover Zepbound; many don't. Medicare Part D generally does not cover obesity drugs. Medicaid coverage varies by state. Check your formulary with your insurer.
What's the difference between the pen and the vial?
Zepbound comes in both pre-filled pens (convenient, higher list price) and single-dose vials (lower price via LillyDirect Self Pay). The medication is the same — delivery format differs. Vial requires self-measured injection with an insulin syringe.
Is compounded tirzepatide still available?
No. The FDA declared the tirzepatide shortage resolved December 19, 2024. 503A compounding discretion ended February 18, 2025; 503B by March 19, 2025. Compounded tirzepatide is no longer broadly legal in the US. See our FDA timeline.
What if I can't afford it?
Start with LillyDirect Self Pay ($349-$499/mo for vial), explore patient assistance (Lilly Cares Foundation for low-income uninsured), or talk to your clinician about whether a different GLP-1 with better coverage fits your situation.